64 related articles for article (PubMed ID: 25669950)
1. Experimental treatment of antipsychotic-induced movement disorders.
Shireen E
J Exp Pharmacol; 2016; 8():1-10. PubMed ID: 27540314
[TBL] [Abstract][Full Text] [Related]
2. The Impact of High-density Lipoprotein Cholesterol (HDL-C) Levels and Risk of Movement Disorders in Patients Taking Antipsychotics.
O'Donnell C; Demler TL; Trigoboff E; Lee C
Innov Clin Neurosci; 2024; 21(4-6):27-30. PubMed ID: 38938537
[TBL] [Abstract][Full Text] [Related]
3. Central European Group on Genetics of Movement Disorders.
Ostrozovicova M; Dusek P; Grofik M; Han V; Holly P; Jech R; Klivenyi P; Kovacs N; Kulcsarova K; Kurca E; Lackova A; Magocova V; Necpal J; Pinter D; Ruzicka E; Serranova T; Smilowska K; Straka I; Svorenova T; Tamas G; Valkovic P; Zarubova K; Houlden H; Rizig M; Skorvanek M
Eur J Neurol; 2024 Apr; 31(4):e16165. PubMed ID: 38059386
[No Abstract] [Full Text] [Related]
4. Tardive Dyskinesia in Older Persons Taking Antipsychotics.
Citrome L; Isaacson SH; Larson D; Kremens D
Neuropsychiatr Dis Treat; 2021; 17():3127-3134. PubMed ID: 34703232
[TBL] [Abstract][Full Text] [Related]
5. Impact of a pharmacist-driven tardive dyskinesia screening service.
Butala N; Williams A; Kneebusch J; Mitchell M
Ment Health Clin; 2021 Jul; 11(4):248-253. PubMed ID: 34316421
[TBL] [Abstract][Full Text] [Related]
6. Tardive Dyskinesia: Treatment Update.
Arya D; Khan T; Margolius AJ; Fernandez HH
Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
[TBL] [Abstract][Full Text] [Related]
7. Medication-Induced Tardive Dyskinesia: A Review and Update.
Cornett EM; Novitch M; Kaye AD; Kata V; Kaye AM
Ochsner J; 2017; 17(2):162-174. PubMed ID: 28638290
[TBL] [Abstract][Full Text] [Related]
8. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
Barnes TR
Psychiatr Dev; 1987; 5(4):301-19. PubMed ID: 2895467
[TBL] [Abstract][Full Text] [Related]
9. [Risk factors for tardive movement disorders in schizophrenia].
Tenback DE; Bakker PR; van Harten PN
Tijdschr Psychiatr; 2015; 57(2):120-4. PubMed ID: 25669950
[TBL] [Abstract][Full Text] [Related]
10. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
Novick D; Haro JM; Bertsch J; Haddad PM
J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
[TBL] [Abstract][Full Text] [Related]
11. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study.
Ryu S; Yoo JH; Kim JH; Choi JS; Baek JH; Ha K; Kwon JS; Hong KS
J Clin Psychopharmacol; 2015 Feb; 35(1):13-21. PubMed ID: 25485636
[TBL] [Abstract][Full Text] [Related]
12. Tardive dyskinesia and deficit schizophrenia.
Telfer S; Shivashankar S; Krishnadas R; McCreadie RG; Kirkpatrick B
Acta Psychiatr Scand; 2011 Nov; 124(5):357-62. PubMed ID: 21838740
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of tardive dyskinesia Part I.
Pineau R; Lachance R; Pelchat G; Jus K; Pires P; Pires P; Villenueve
Dis Nerv Syst; 1976 Apr; 37(4):210-4. PubMed ID: 3394
[TBL] [Abstract][Full Text] [Related]
14. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia.
Seeman P; Tinazzi M
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():178-83. PubMed ID: 23454261
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
